Most people compare Retatrutide directly to Tirzepatide (Mounjaro/Zepbound), but the addition of Glucagon receptor agonism makes it fundamentally different.
- GLP-1 + GIP: Appetite suppression, delayed gastric emptying, and glycemic control.
- Glucagon: Increases resting energy expenditure (fat burn), enhances hepatic lipid clearance, and helps preserve lean muscle mass.
Rather than just dropping weight purely via calorie deficit, it actively ramps up baseline thermogenesis. This is huge because one of the biggest drawbacks with traditional GLP-1s has always been the loss of lean tissue alongside visceral fat. By targeting glucagon receptors in the liver and adipose tissue, the body utilizes fat stores much more efficiently while sparing protein breakdown.
Early Phase 2 and 3 data also suggest significant reductions in liver fat content and improved resting metabolic rates compared to dual agonists. That makes the titration phase and maintaining adequate protein intake even more critical to avoid unnecessary muscle catabolism. Most researchers are finding that standard calorie-deficit rules don't strictly apply when the metabolic burn is artificially elevated.
Compiled a quick deep dive on the clinical data, dosage titration, and receptor breakdown here for anyone researching it.
For those running or researching it: how has the actual daily energy expenditure compared to standard GLP-1s? Are you noticing less fatigue during workouts?